Project Grant R44TR003162

Khloris Biosciences, Inc. received a $3.46 million Project Grant from the National Institutes of Health National Heart, Lung and Blood Institute to develop and validate a collection of induced pluripotent stem cell-derived cardiomyocyte cell lines. Under the Cardiovascular Diseases Research program (CFDA 93.837), Khloris will establish 50 cell lines from healthy individuals and patients with common hereditary cardiac disorders such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and long...

This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $590,283 to the University of Wisconsin-Madison to develop robust, closed-loop manufacturing processes for producing human pluripotent stem cell-derived cardiomyocytes. The overarching goal is to improve the reproducibility and scalability of cardiomyocyte differentiation through integrated single-cell transcriptomic and...

This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...

This $402,403 federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development of a high-throughput functional assessment platform using human cardiospheres (3D human cardiomyocyte cultures) to detect and evaluate chemotherapy-induced cardiotoxicity. The key objectives are to: (1) establish a high-throughput platform to assess cardiac calcium handling and functional changes in human cardiospheres exposed to chemotherapeutic agents,...

This $100,000 Project Grant from the National Science Foundation Division of Chemical, Bioengineering, Environmental, and Transport Systems supports the development of a 3D human stem cell cardiac model for cardiac electrophysiology medical device safety assessment. Funded under the NSF Engineering program (CFDA 47.041), this award will allow the University of Maryland, College Park to create a novel in vitro model for evaluating the safety and efficacy of cardiac medical devices through January...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...

This $1,000,000 National Science Foundation project grant supports research at the University of Wisconsin-Madison to develop single cell-level programming of human induced pluripotent stem cell differentiation into chamber-specific cardiomyocytes. The goal is to generate cardiomyocytes from each chamber of the heart through precise control of Wnt and retinoic acid signaling at the single cell level via engineered genetic programs and superstructures. If successful, this approach could establish...

This National Science Foundation (NSF) Engineering Program (CFDA 47.041) Project Grant award of $600,000 to Dartmouth College aims to develop methodologies for efficiently manufacturing mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to accelerate drug development and cardiac disease modeling. The project will employ biochip design, machine learning, developmental biology, and tissue engineering approaches to enhance the structural and functional maturity of...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,249,307 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University to conduct research on targeting the dysregulated maturation program in pluripotent-derived cardiomyocytes (PSC-CMs). The project aims to test the role of a conserved gene regulatory network in overcoming the premature arrest of PSC-CMs, which remain immature in phenotype and function, to improve their clinical...